TG THERAPEUTICS, INC.
About TG THERAPEUTICS, INC.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, it has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. Its pipeline includes UBLITUXIMAB, SUB-Q UBLITUXIMAB, and AZER-CEL. Geographically, it generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from the international market.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $616.3M
- Net income
- $447.2M
- Total assets
- $1.1B
- Market cap
- $6.1B
- Gross margin
- 83.7%
- Operating margin
- 20.0%
- Net margin
- 72.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $616.3M
- Cost of revenue
- $100.7M
- Gross profit
- $515.6M
- Operating expenses
- $392.2M
- Operating income
- $123.3M
- Income tax
- -$339.8M
- Net income
- $447.2M
- EPS (basic)
- $3.10
- EPS (diluted)
- $2.77
Balance sheet
- Total assets
- $1.1B
- Current assets
- $630.8M
- Total liabilities
- $415.2M
- Current liabilities
- $153.8M
- Shareholders’ equity
- $648.0M
Cash flow
- Operating cash flow
- -$24.8M
- Investing cash flow
- $13.8M
- Financing cash flow
- -$89.7M
- Net cash flow
- -$100.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $6.1B
- P/E ratio
- 16.8
- EPS (diluted)
- $2.77
- Shares outstanding
- 131.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 14, 1995
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $447.2M in FY2025.
- Revenue grew 9113% from FY2021 to FY2025.
- Gross margin of 83.7%, net margin 72.6%.
- Trading near its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 16.8.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review TG THERAPEUTICS, INC..
Write a review
News about TG THERAPEUTICS, INC.
News & sentiment via Polygon.io
